Literature DB >> 27530215

Hiv-2 molecular epidemiology.

Benoit Visseaux1, Florence Damond2, Sophie Matheron3, Diane Descamps2, Charlotte Charpentier2.   

Abstract

The Simian Immunodeficiency Virus of sooty mangabeys (SIVsmm) has been revealed to be at the origin of Human Immunodeficiency Virus type 2 (HIV-2) in humans, firstly detected from two Portuguese patients in 1986. HIV-2 is mainly restricted to West Africa where it infects up to 1 to 2 million people. HIV-2 is also present in Europe, mainly Portugal and France, India and United States of America. Two major HIV-2 groups, groups A and B, were generated by two independent transmission events involving infected sooty mangabeys from the Taï forest in Ivory Coast. Seven other HIV-2 groups have been described, but each has only been identified in one patient. To date, no subtypes have been formally described but some preliminary data suggest that HIV-2 group A may be divided in two distinct subtypes with distinct geographical origins. To date only two recombinant forms have been described: one circulating recombinant form (CRF01_AB) and one unique recombinant form. In this review, we focused mainly on molecular data available and their insights about HIV-2 origins, diversity, drug resistance and global epidemiology. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology; Genetic diversity; HIV-2; West Africa

Mesh:

Year:  2016        PMID: 27530215     DOI: 10.1016/j.meegid.2016.08.010

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  24 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.

Authors:  Mélanie Bertine; Marie Gueudin; Adeline Mélard; Florence Damond; Diane Descamps; Sophie Matheron; Fidéline Collin; Christine Rouzioux; Jean-Christophe Plantier; Véronique Avettand-Fenoel
Journal:  J Clin Microbiol       Date:  2017-07-12       Impact factor: 5.948

3.  A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.

Authors:  Xiaoran Tang; Hongliang Jin; Yue Chen; Li Li; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

4.  Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2.

Authors:  Elena Heusinger; Katja Deppe; Paola Sette; Christian Krapp; Dorota Kmiec; Silvia F Kluge; Preston A Marx; Cristian Apetrei; Frank Kirchhoff; Daniel Sauter
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

5.  MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.

Authors:  Vincent H Wu; Robert A Smith; Sara Masoum; Dana N Raugi; Selly Ba; Moussa Seydi; Jay A Grobler; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.

Authors:  Morgan E Meissner; Nora A Willkomm; Jamie Lucas; William G Arndt; Sarah F Aitken; Emily J Julik; Sunanda Baliga; Louis M Mansky
Journal:  J Mol Biol       Date:  2021-11-10       Impact factor: 5.469

7.  Molecular Biology and Diversification of Human Retroviruses.

Authors:  Morgan E Meissner; Nathaniel Talledge; Louis M Mansky
Journal:  Front Virol       Date:  2022-06-02

8.  Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients.

Authors:  Pedro Borrego; Maria Fátima Gonçalves; Perpétua Gomes; Lavínia Araújo; Inês Moranguinho; Inês Brito Figueiredo; Isabel Barahona; José Rocha; Claudino Mendonça; Maria Cesarina Cruz; Jorge Barreto; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2017-05-17       Impact factor: 5.948

9.  In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Authors:  Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 10.  Delayed disease progression in HIV-2: the importance of TRIM5α and the retroviral capsid.

Authors:  M T Boswell; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2019-03-21       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.